"Ultra-low" doses of the drug rituximab may be enough to keep some patients' rheumatoid arthritis under control for several years, a new, preliminary study suggests.
Many American arthritis sufferers aren't getting any exercise despite its benefits for reducing pain and improving their quality of life, new research shows.
